Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CTLA-4 (clone 9H10)
- Development stage
- Preclinical
- Lead developer
- Bio X Cell
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraperitoneal Injection
01
Overview
Anti-CTLA-4 (clone 9H10) is a Syrian hamster monoclonal antibody that specifically targets murine Cytotoxic T-Lymphocyte-Associated protein 4 (CTLA-4, also known as CD152). CTLA-4 is a critical immune checkpoint molecule expressed on the surface of activated T cells and regulatory T cells (Tregs). It functions as a negative regulator of T cell immune responses by outcompeting the costimulatory receptor CD28 for binding to its ligands, CD80 (B7-1) and CD86 (B7-2), on antigen-presenting cells. Clone 9H10 is a widely utilized research tool in preclinical oncology and immunology studies to achieve CTLA-4 blockade. By preventing CTLA-4-mediated inhibition, the antibody enhances T cell proliferation, effector function, and antitumor immunity. In recent research, clone 9H10 has been used in mouse models (such as B16F10 melanoma and MC38 colorectal cancer) to investigate the therapeutic window of checkpoint inhibitors and the management of immune-related adverse events (irAEs) using sequential CTLA-4 Ig treatment.
- Other names
- anti-mCTLA-4 clone 9H10anti-mCTLA4 clone 9H10anti-mCTLA 4 clone 9H10hamster anti-mouse CTLA-4 clone 9H10
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)FCGR3B (Fc gamma receptor III)
Beyond the preview
Go deeper on anti-CTLA-4 (clone 9H10).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CTLA-4 (clone 9H10).